# William Blair & Company, L.L.C.

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/william-blair-company-llc
Canonical HTML page: https://getyourbrief.com/entity/william-blair-company-llc

## Timeline

- **2026-08-20**: H1 2026 results announced — Telix released its half-year results, reporting US$68 million invested in therapeutics R&D and highlighting late-stage program ProstACT Global.
- **2026-08-20**: ATM facility established — Telix entered into an equity distribution agreement with Morgan Stanley & Co. LLC and William Blair & Company, L.L.C. to establish an at-the-market equity facility for ADS issuance at prevailing market prices.
- **2026-06-30**: H1 2026 reporting period ended — Telix's half-year financial reporting period closed for the six months ended June 30, 2026.

## Recent coverage (3 stories, network-wide)

### Telix H1 2026: $68M R&D Fuels Precision Medicine Manufacturing Push
2026-08-20 18:11:37 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

For healthcare and health IT leaders, Telix's half-year update is a supply-chain signal: the company is expanding radiopharmaceutical manufacturing across four countries to support precision medicine demand. The US$68 million therapeutics R&D investment and TMS expansion point to more reliable access to short-lived isotopes.
Full story: https://gethealthbrief.com/story/telix-h1-2026-precision-medicine-manufacturing

### Telix Adds ATM Facility, $68M R&D Spend in H1 2026 Results
2026-08-20 18:11:28 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2

For investors, Telix's H1 2026 announcement is dominated by the same-day creation of an at-the-market equity facility with Morgan Stanley and William Blair. The release provides US$68 million in disclosed therapeutics R&D but omits revenue and profit totals in the syndicated excerpt.
Full story: https://getfinancebrief.com/story/telix-h1-2026-atm-facility-68m-rd

### Telix H1: $68M R&D, ProstACT Global Advances Late-Stage Pipeline
2026-08-20 18:11:17 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

For biotech and pharma teams, Telix's update confirms a shift toward therapeutic radiopharmaceuticals. The company says it invested US$68 million in the therapeutics pipeline and advanced ProstACT Global, although the press release omits detailed trial data.
Full story: https://getbiobrief.com/story/telix-h1-2026-prostact-global-68m-rd

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.